Texas' top court nixes $32M Vioxx award

Merck ($MRK) won a reversal of the $32 million jury verdict in a Texas case over the Vioxx painkiller. The state's Supreme Court decided that the family of Leonel Garza didn't produce enough evidence to show Vioxx caused his heart attack, thus tossing out the 2006 verdict. Report

Suggested Articles

Doctor putting stethescope to patient's chest
Pharma

Esperion scores FDA nod for cholesterol-buster Nexletol

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

by Kyle Blankenship
Lundbeck
Pharma

Lundbeck scores FDA nod in crowded migraine prevention field

The FDA approved Lundbeck's Vyepti, formerly known as eptinezumab, as the first IV therapy to prevent migraines in adults.

by Eric Sagonowsky
Kåre Schultz
Pharma

'Boring is good,' Teva CEO says amid push to remove risk

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

by Eric Sagonowsky